A Type III Complement Factor D Deficiency: Structural insights for inhibition of the alternative pathway

Autor: Sng, CCT, O’Byrne, S, Prigozhin, DM, Bauer, MR, Harvey, JC, Ruhle, M, Challis, BG, Lear, S, Roberts, LD, Workman, S, Janowitz, T, Magiera, L, Doffinger, R, Buckland, MS, Jodrell, DJ, Semple, RK, Wilson, TJ, Modis, Y, Thaventhiran, JED

Publikováno v: The Journal of Allergy and Clinical Immunology
Sng, C C T, O'Byrne, S, Prigozhin, D M, Bauer, M R, Harvey, J C, Ruhle, M, Challis, B G, Lear, S, Roberts, L D, Workman, S, Janowitz, T, Magiera, L, Doffinger, R, Buckland, M S, Jodrell, D J, Semple, R K, Wilson, T J, Modis, Y & Thaventhiran, J E D 2018, ' A type III complement factor D deficiency : Structural insights for inhibition of the alternative pathway ', Journal of Allergy and Clinical Immunology . https://doi.org/10.1016/j.jaci.2018.01.048
The Journal of allergy and clinical immunology, vol 142, iss 1
Sng, Christopher CT; O'Byrne, Sorcha; Prigozhin, Daniil M; Bauer, Matthias R; Harvey, Jennifer C; Ruhle, Michelle; et al.(2018). A type III complement factor D deficiency: Structural insights for inhibition of the alternative pathway.. The Journal of allergy and clinical immunology, 142(1), 311-314.e6. doi: 10.1016/j.jaci.2018.01.048. Lawrence Berkeley National Laboratory: Retrieved from: http://www.escholarship.org/uc/item/9j831648

Background: Complement factor D (FD) is the rate-limiting enzyme of the alternative complement pathway. Previous reports of FD deficiency featured absent plasma FD (type I deficiency) and susceptibility to meningococcal infection. A new FD mutant, wh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3b02c12330f21d271d04b9136ea250fb
https://eprints.whiterose.ac.uk/128452/8/1-s2.0-S0091674918303270-main.pdf

Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer.

Autor: Pinato DJ; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy., Ferrante D; Department of Translational Medicine, Unit of Medical Statistics, University of Piemonte Orientale, Novara, Italy., Aguilar-Company J; Medical Oncology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall D'Hebron University Hospital, Barcelona, Spain., Bower M; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK., Salazar R; Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Spain., Mirallas O; Medical Oncology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Sureda A; Haematology Department, ICO Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain., Bertuzzi A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Brunet J; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Lambertini M; Medical Oncology Department, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy., Maluquer C; Haematology Department, ICO Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain., Pedrazzoli P; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia Italy., Biello F; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy., Lee AJX; Cancer Division, University College London Hospitals, London, UK., Sng CCT; Cancer Division, University College London Hospitals, London, UK., Liñan R; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Rossi S; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Carmona-García MC; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Sharkey R; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK., Eremiev S; Medical Oncology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Rizzo G; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Bain HD; Cancer Division, University College London Hospitals, London, UK., Yu T; Cancer Division, University College London Hospitals, London, UK., Cruz CA; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain., Perachino M; Medical Oncology Department, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy., Saoudi-Gonzalez N; Medical Oncology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Fort-Culillas R; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Doonga K; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK., Fox L; Department of Hematology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Roldán E; Medical Oncology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Zoratto F; Medical Oncology, St Maria Goretti Hospital, Latina, Italy., Gaidano G; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore Della Carità Hospital, Novara, Italy., Ruiz-Camps I; Infectious Diseases, Vall D'Hebron University Hospital, Barcelona, Spain., Bruna R; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore Della Carità Hospital, Novara, Italy., Patriarca A; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore Della Carità Hospital, Novara, Italy., Shawe-Taylor M; Cancer Division, University College London Hospitals, London, UK., Fusco V; Oncology Unit and Centro Documentazione Osteonecrosi, Azienda Ospedaliera 'SS Antonio e Biagio e Cesare Arrigo', Alessandria, Italy., Martinez-Vila C; Fundació Althaia Manresa, Manresa, Spain., Berardi R; Medical Oncology, AOU Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy., Filetti M; Medical Oncology, St. Andrea Hospital, Rome, Italy., Mazzoni F; Medical Oncology, Careggi University Hospital, Florence, Italy., Santoro A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 20090 Pieve Emanuele, Milan, Italy., Delfanti S; Mesothelioma Unit, Azienda Ospedaliera SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy., Parisi A; Department of Life, Health & Environmental Sciences, University of L'Aquila, L'Aquila, Italy., Queirolo P; Melanoma and Sarcoma Medical Treatment Unit, IEO - Istituto Europeo di Oncologia, Milan, Italy., Aujayeb A; Respiratory Department, Northumbria Healthcare NHS Foundation Trust, North Shields, UK., Rimassa L; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 20090 Pieve Emanuele, Milan, Italy., Prat A; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain., Tabernero J; Medical Oncology, Vall D'Hebron University Hospital and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain., Gennari A; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy., Cortellini A; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK. Electronic address: alessiocortellini@gmail.com.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2022 Aug; Vol. 171, pp. 64-74. Date of Electronic Publication: 2022 May 23.

Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study.

Autor: Pinato DJ; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. Electronic address: david.pinato@imperial.ac.uk., Scotti L; Unit of Cancer Epidemiology, Department of Translational Medicine, CPO-Piemonte, University of Piemonte Orientale, Novara, Italy., Gennari A; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy., Colomba-Blameble E; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, 114 Rue Edouard Vaillant, 94800, Villejuif, France., Dolly S; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK., Loizidou A; Department of Infectious Diseases, Internal Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium., Chester J; Medical Oncology, School of Medicine, Cardiff University, Cardiff, UK; Medical Oncology, Velindre Cancer Centre, Cardiff, UK., Mukherjee U; Medical Oncology, Barts Health NHS Trust, London, UK., Zambelli A; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Aguilar-Company J; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain., Bower M; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK., Galazi M; Cancer Division, University College London Hospitals, London, UK., Salazar R; Department of Medical Oncology, ICO L'Hospitalet, Oncobell Program (IDIBELL), CIBERONC, Hospitalet de Llobregat, Spain., Bertuzzi A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089, Milan, Italy., Brunet J; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Mesia R; Department of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain., Sita-Lumsden A; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK., Colomba J; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, 114 Rue Edouard Vaillant, 94800, Villejuif, France., Pommeret F; Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, 114 Rue Edouard Vaillant, 94800, Villejuif, France., Seguí E; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain., Biello F; Division of Oncology, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy., Generali D; Multidisciplinary Breast Pathology and Translational Research Unit, ASST Cremona, Italy; Department of Medical, Surgical and Health Sciences, University of Trieste, Italy., Grisanti S; Medical Oncology Unit, Spedali Civili, Brescia, Italy., Rizzo G; Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Libertini M; Medical Oncology Unit, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy., Moss C; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Evans JS; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK., Russell B; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Wuerstlein R; Department of Gynecology and Obstetrics, Breast Center and Gynecological Cancer Center and CCC Munich, University Hospital Munich, Munich, Germany., Vincenzi B; Policlinico Universitario Campus Bio-Medico, Rome, Italy., Bertulli R; Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ottaviani D; Cancer Division, University College London Hospitals, London, UK., Liñan R; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Marrari A; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089, Milan, Italy., Carmona-García MC; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Sng CCT; Cancer Division, University College London Hospitals, London, UK., Tondini C; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Mirallas O; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Tovazzi V; Medical Oncology Unit, Spedali Civili, Brescia, Italy., Fotia V; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Cruz CA; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain., Saoudi-Gonzalez N; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Felip E; Department of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain., R Lloveras A; Department of Medical Oncology, Catalan Institute of Oncology, University Hospital Josep Trueta, Girona, Spain., Lee AJX; Cancer Division, University College London Hospitals, London, UK., Newsom-Davis T; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK., Sharkey R; Department of Oncology and National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, UK., Chung C; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK., García-Illescas D; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain., Reyes R; Department of Medical Oncology, Hospital Clinic, Barcelona, Spain., Sophia Wong YN; Cancer Division, University College London Hospitals, London, UK., Ferrante D; Unit of Cancer Epidemiology, Department of Translational Medicine, CPO-Piemonte, University of Piemonte Orientale, Novara, Italy., Marco-Hernández J; Department of Internal Medicine, Hospital Clinic, Barcelona, Spain., Ruiz-Camps I; Infectious Diseases, Vall d'Hebron University Hospital, Barcelona, Spain., Gaidano G; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore della Carità Hospital, Novara, Italy., Patriarca A; Division of Haematology, Department of Translational Medicine, University of Piemonte Orientale and Maggiore della Carità Hospital, Novara, Italy., Sureda A; Haematology Department, ICO Hospitalet, Hospitalet de Llobregat, IDIBELL, Universitat de Barcelona, Barcelona, Spain., Martinez-Vila C; Fundació Althaia Manresa, Manresa, Spain., Sanchez de Torre A; Hospital Universitario XII de Octubre Madrid, Spain., Rimassa L; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 20090 Pieve Emanuele, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089, Milan, Italy., Chiudinelli L; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Franchi M; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy., Krengli M; Division of Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale and Azienda Ospedaliera Maggiore Della Carita, Novara, Italy., Santoro A; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 20090 Pieve Emanuele, Milan, Italy; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089, Milan, Italy., Prat A; Department of Medical Oncology, Catalan Institute of Oncology, Badalona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain., Tabernero J; Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain., V Hemelrijck M; Medical Oncology, Guy's and St Thomas' NHS Foundation Trust (GSTT), London, UK; Translational Oncology and Urology Research (TOUR), School of Cancer and Pharmaceutical Sciences, King's College London, London, UK., Diamantis N; Medical Oncology, Barts Health NHS Trust, London, UK., Cortellini A; Department of Surgery & Cancer, Imperial College London, Hammersmith Hospital, London, UK; Department of Biotechnology and Applied Clinical Sciences, University of L'Aquila, Via Vetoio, 67100, L'Aquila, Italy. Electronic address: a.cortellini@imperial.ac.uk.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Jun; Vol. 150, pp. 190-202. Date of Electronic Publication: 2021 Apr 06.

Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience.

Autor: Sng CCT; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Wong YNS; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom.; UCL Cancer Institute, University College London, London, United Kingdom., Wu A; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Ottaviani D; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Chopra N; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Galazi M; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Benafif S; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Soosaipillai G; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom., Roylance R; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom.; NIHR University College London Hospitals Biomedical Research Centre, London, United Kingdom., Lee AJX; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom.; UCL Cancer Institute, University College London, London, United Kingdom., Shaw H; Cancer Division, University College London Hospitals NHS Foundation Trust, London, United Kingdom.

Publikováno v: Frontiers in oncology [Front Oncol] 2020 Nov 20; Vol. 10, pp. 595804. Date of Electronic Publication: 2020 Nov 20 (Print Publication: 2020).